Well, sorry to hear you got sacked, but im sure you are better off.
That said, there is significant resposibility on the company/reps to deny MDs access to products that they well know are not in the most competent hands. Yes, ISI is responsible to its shareholders first. Unfortunately, the short term win of driving bad usage will be a long term loss for shareholders, patients and providers. This tech, in the propper hands for appropriate procedures, can actually provide a clinical benefit. But ISI f*cked it royally with over selling, empty promises, inflated claims and high pressure sales tactics. You put revenue ahead of patient outcomes. That will only last so long.